Boundless Bio Inc News - BOLD

SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc. PR Newswire NEW YORK, Dec. 3, 2019...

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company - Audentes to operate as an...

Audentes Therapeutics to Participate in Upcoming Investor Conferences

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Amended Statement of Ownership (sc 13g/a)

SCHEDULE 13G Amendment No. 5 AUDENTES THERAPEUTICS INC COMMON STOCK Cusip #05070R104 Check the appropriate box to...

Quarterly Report (10-q)

false--12-31Q32019000162873814201000292000169500020000.000010.00001300000000300000000435467864574057543546786457405750000100000P5Y0.000010.0000...

Current Report Filing (8-k)

false0001628738 0001628738 2019-11-07 2019-11-07 UNITED STATES SECURITIES AND EXCHANGE...

Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- BLA submission for AT132 for the treatment of XLMTM on-track for mid-2020; MAA on-track for second half of 2020 - Continued progress in Pompe...

Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2...

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative...

Current Report Filing (8-k)

false0001628738 0001628738 2019-10-05 2019-10-05 UNITED STATES SECURITIES AND EXCHANGE...

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked M...

- First seven treated patients now ventilator independent and able to rise to a standing position or walk - Continued significant and durable...

Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative...

Audentes Therapeutics to Participate in Upcoming Investor Conferences

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative...

Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including Ne...

- Oral presentation of ASPIRO results to include additional efficacy and safety data on all patients in dose Cohort 1 and the first treated...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Boundless Bio Inc (BOLD)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

BOLD News

SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

Audentes Therapeutics to Participate in Upcoming Investor Conferences

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Ownership (sc 13g/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2...

Current Report Filing (8-k)

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked M...

Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audentes Therapeutics to Participate in Upcoming Investor Conferences

Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including Ne...

Statement of Changes in Beneficial Ownership (4)

BOLD Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Boundless Bio Inc (BOLD) News

Boundless Bio Inc (BOLD)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

BOLD News

SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

Audentes Therapeutics to Participate in Upcoming Investor Conferences

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Ownership (sc 13g/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2...

Current Report Filing (8-k)

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked M...

Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audentes Therapeutics to Participate in Upcoming Investor Conferences

Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including Ne...

Statement of Changes in Beneficial Ownership (4)

BOLD Discussion

Your Recent History